Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Pharmaceutical Technology

AUGUST 23, 2022

It comprises messenger ribonucleic acid (mRNA) that encodes for the initial spike protein of SARS-CoV-2 along with mRNA that encodes for Omicron BA.4/BA.5 5 variant spike protein. The companies have also commenced rolling submission for conditional marketing authorization from the European Medicines Agency (EMA) for this Omicron BA.4/BA.5-adapted

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

Pharmaceutical Technology

NOVEMBER 9, 2022

CSL Behring has a commercialisation and license agreement to develop EtranaDez. Haemophilia A is caused by insufficient levels of the clotting protein factor VIII, while patients with haemophilia B lack adequate factor IX levels. A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278

pharmaphorum

JANUARY 21, 2021

This is the first project to be funded by the international Psychiatry Consortium, a £4 million collaboration between seven global pharmaceutical companies, and two leading research charities, convened and managed by the Medicines Discovery Catapult, that supports high-value drug discovery projects in this area of unmet patient need.

Medicine 111

Medicine Protein Drugs Research 111

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.

Licensing 52

Licensing Licensing Sales Marketing 52

pharmaphorum

JANUARY 11, 2023

Anima uses its mRNA Lightning platform to discover small molecules and determine their mechanisms of action for diseases previously deemed undruggable, with scientists searching for compounds that target proteins with roles in regulating mRNA, so as to affect disease states through post-transcriptional regulation (i.e.

Protein 105

Protein Regulation FDA Approval Licensing 105

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

XTalks

JANUARY 29, 2021

They are both checkpoint inhibitors targeted towards programmed cell death protein 1 (PD-1 inhibitors), a protein that is responsible for downregulating the immune system and preventing it from killing cancer cells. Biosimilars are increasingly becoming the standard of care and both have several licensed biosimilar drugs (e.g.

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. synuclein protein, mainly in oligodendroglial cells (glial cytoplasmic inclusions) and also in certain nerve cells.

Licensing 52

Licensing Licensing Drugs Development 52

Pfizer

SEPTEMBER 28, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted 5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. Tue, 09/27/2022 - 16:15. Wednesday, September 28, 2022 - 11:45am.

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

pharmaphorum

DECEMBER 2, 2021

GlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply machine learning and functional genomics to the discovery of new medicines. Most notable is GSK’s $700 million upfront deal in the summer to license two drugs for neurological disease developed by US biotech Alector.

Biobanking 93

Biobanking Genomics Genome Genetics 93

Drug Discovery Today

APRIL 22, 2020

Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license (..)

Licensing 40

Licensing Licensing Genomics Genome 40

pharmaphorum

DECEMBER 21, 2021

The US biotech’s other main platform is XTEN, which adds side chains to existing molecules to extend their activity in the body and prevent off-target effects, and has already been licensed to other drugmakers including Biogen and Merck & Co. Sanofi’s other acquisitions this year were the $3.2 billion upfront.

Licensing 124

Licensing Licensing Protein Clinical Development 124

pharmaphorum

DECEMBER 21, 2020

Compared with many of the established names in pharma these companies are young upstarts but they have managed to achieve what other big names in the industry have failed to do and harness the power of mRNA to make medicine. In this case that is the “spike” protein seen on the surface of the coronavirus that it uses to invade host cells.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

XTalks

DECEMBER 20, 2021

It has also applied for regulatory licensing in the UK, European Union (EU), Australia, Singapore, India, United Arab Emirates (UAE), New Zealand and Japan. Covovax is a recombinant protein-based vaccine and can be regarded as a more “traditional” vaccine as it isn’t genetic-based like mRNA or viral vector vaccines. Gavi secured 1.1

Vaccination 96

Vaccination Vaccine Protein Manufacturing 96

pharmaphorum

MARCH 8, 2021

The EMA’s human medicines committee has said two Eli Lilly antibodies are effective in people with COVID-19 who are at risk of developing severe disease, clearing the way for use in EU member states.

Antibody 105

Antibody Licensing Licensing Protein 105

XTalks

JANUARY 4, 2024

Hemophilia B, also known as congenital Factor IX (FIX) deficiency or Christmas disease, is a rare genetic bleeding disorder caused by a deficiency or defect in the FIX clotting protein. Treatment involves replacing the missing FIX clotting protein, traditionally through regular infusions. Priced at $3.5

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

pharmaphorum

FEBRUARY 4, 2022

” Nuvaxovid was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) yesterday, becoming the fifth COVID-19 vaccine to be authorised in the UK. In August 2020, the UK government agreed a deal with Novavax to purchase 60 million doses of the vaccine.

Vaccination 98

Vaccination Vaccine Protein Manufacturing 98

pharmaphorum

JULY 5, 2022

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic exposure to loud noises. An estimated 1.57

In-Vivo 110

In-Vivo Bioinformatics Genetics Licensing 110

pharmaphorum

JUNE 4, 2021

The Noria/PSMA deal gives the drugmaker a preclinical-stage alpha radionuclide compound based on actinium-225 and a small molecule directed towards prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed in prostate cancer.

Antibody 81

Antibody Licensing Licensing Protein 81

Pharmaceutical Technology

AUGUST 26, 2008

As understanding of biological systems has forged ahead, pharmaceutical companies have made increasing use of biotechnology in discovering and manufacturing new medicines. ” Today most big pharmaceutical companies are pursuing biotechnology either in house or by using an in-licensing strategy.

Antibody 100

Antibody Licensing Licensing Production 100

The Pharma Data

SEPTEMBER 8, 2020

Fourteen newly licensed medicines have been accepted for use on NHS Scotland by the Scottish Medicines Consortium (SMC), bringing a raft of new treatment options for conditions including epilepsy, depression and cancer.

Medicine 52

Medicine Clinical Trials Clinical Trials Drugs 52

pharmaphorum

OCTOBER 3, 2022

DMD is a severe, progressive muscle-wasting genetic condition caused by the lack of a protein called dystrophin. Translarna was the first licensed treatment for DMD which addresses the loss of dystrophin. Eventually, they will need assistance with breathing.

Gene Therapy 98

Gene Therapy Gene FDA Approval DNA 98

Pharmaceutical Technology

FEBRUARY 14, 2023

Alkaloids, natural dyes, drugs, proteins, and enzymes are some of the important classes of natural heterocyclic compounds essential for human life. The most common heteroatoms are nitrogen (N), oxygen (O) and sulphur (S). Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects.

Antibody 130

Antibody Hormones DNA Licensing 130

pharmaphorum

JANUARY 3, 2023

SPK-9001 is a novel, investigation vector containing a bio-engineered adeno-associated virus (AAV) capsid (protein shell) and a high-activity human coagulation FIX gene. Additional key data is to be presented at scientific conference early this year.

Gene Therapy 98

Gene Therapy Gene Medicine Trials 98

pharmaphorum

SEPTEMBER 13, 2022

.” If Lamzede is approved by the FDA, it will be another milestone for Chiesi’s two-year-old rare disease division , based in Boston, which was formed to diversify away from the company’s traditional focus on respiratory medicines and further its ambition to grow in the US.

Drugs 105

Drugs Licensing Licensing Production 105

The Pharma Data

AUGUST 17, 2020

. (“Dragonfly”), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life cytokine DF6002. About Bristol Myers Squibb.

Licensing 52

Licensing Licensing Development Production 52

The Pharma Data

JUNE 14, 2023

Cedilla’s small molecules conditionally modulate the protein complex in its functional state resulting in highly selective inhibition. Cedilla will also be eligible to receive royalties on medicines based on their technology commercialized by Bayer. Financial details have not been disclosed.

Licensing 40

Licensing Licensing Life Science Development 40

The Pharma Data

NOVEMBER 29, 2020

Binding to the MDM2 protein with high affinity, MDM2 inhibitor blocks the MDM2-p53 interactions and restore the tumor-suppressing activity of p53. Binding to the MDM2 protein with high affinity, MDM2 inhibitor blocks the MDM2-p53 interactions and restore the tumor-suppressing activity of p53. SUZHOU, China and ROCKVILLE, Md. ,

Licensing 40

Licensing Licensing Protein Drugs 40

The Pharma Data

DECEMBER 13, 2020

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. . CAMBRIDGE, Mass., 14, 2020 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements.

Licensing 40

Licensing Licensing Clinical Trials Clinical Trials 40

The Pharma Data

JANUARY 24, 2021

“We are delighted to be collaborating with the world-renowned researchers at BIDMC, as their cutting-edge research and development work is crucial in bringing potentially life-saving medicines to patients in need of new treatment options.” ZUG, Switzerland , Jan. Chief Medical Officer of Quercis Pharma.

Licensing 40

Licensing Licensing Clinical Trials Clinical Trials 40

pharmaphorum

JULY 18, 2022

“It is programmed and coded for the production of the full-length spike protein of the coronavirus. It then elicits an immune response against that spike protein. We’ve been inspected by the European Medicines Agency (EMA) and passed the Good Manufacturing Practice (GMP) inspection.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

XTalks

JULY 17, 2023

In a significant development, Astellas Pharma announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had accepted their applications for Priority Review and Marketing Authorization respectively for zolbetuximab. This investigational first-in-class Claudin 18.2 How Does Zolbetuximab Work?

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

XTalks

DECEMBER 13, 2023

These efforts encompass programs related to the shingles vaccine, Tdap vaccine and plague vaccine, reinforcing Dynavax’s commitment to advancing the field of vaccines and medicine. Alpine Immune Sciences has recently announced an augmentation in its R&D investment. million and $38.8 million, respectively, as compared to $17.6

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

APRIL 3, 2024

The RBCs in circulation are marked by proteins in the complement system for removal by the spleen and liver. Through its Alexion deal, AstraZeneca is looking to expand into other rare diseases, including various forms of amyloidosis for which it has secured licensing deals and buyouts.

FDA Approval 102

FDA Approval Sales Trials Development 102

The Pharma Data

JANUARY 5, 2021

Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. This is because many proteins do not have small-molecule binding sites. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins.

RNA 52

RNA Protein Bioavailability DNA 52

XTalks

JANUARY 28, 2022

Immunocore received Breakthrough Device Designation for Kimmtrak from the FDA in February 2021 followed by acceptance of its Biologics License Application (BLA) several months later by both US and European regulators. Kimmtrak is a bispecific protein that contains a soluble T cell receptor fused to an anti-CD3 immune-effector function.

FDA Approval 98

FDA Approval Development Containment Licensing 98